Business context and reporting period
Important entity mismatch: The supplied filing is Zafgen, Inc.’s Form 10-Q for the quarter ended March 31, 2015, not a filing by Larimar Therapeutics, Inc. This summary reflects the filing text provided.
Zafgen was a development-stage biopharmaceutical company focused on beloranib, a MetAP2 inhibitor being developed for obesity and related conditions, and preclinical-stage ZGN-839 for NASH and abdominal obesity. The company reported no product revenue and had not commercialized any product.
Key financial metrics
Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise noted.
| Metric | Q1 2015 | Q1 2014 or prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $10.215 | $3.275 |
| General and administrative expense | $3.025 | $1.246 |
| Total operating expenses | $13.240 | $4.521 |
| Net loss | $13.472 | $4.458 |
| Net loss per common share, basic and diluted | $0.53 | $6.18 |
| Cash used in operating activities | $11.087 | $4.020 |
| Cash and cash equivalents | $106.934 at March 31 | $58.103 at December 31, 2014 |
| Marketable securities | $127.267 at March 31 | $57.359 at December 31, 2014 |
| Total liabilities | $15.052 at March 31 | $13.078 at December 31, 2014 |
Cash, cash equivalents and marketable securities totaled approximately $234.2 million at March 31, 2015. Current assets were $236.3 million and current liabilities were $9.5 million. Notes payable had $7.5 million of principal outstanding; the balance sheet reported $2.093 million current and $5.521 million long-term, net of applicable adjustments. The filing gives an effective annual debt rate of approximately 14% and a stated rate of 8.1%.
Material changes versus the prior comparable period
- Operating expenses rose $8.719 million year over year. R&D increased $6.940 million, principally from beloranib clinical, preclinical and manufacturing work and increased early-stage program spending. G&A increased $1.779 million, reflecting hiring, public-company costs and other expenses.
- Net loss increased $9.014 million. The per-share loss was lower than in Q1 2014, primarily in the context of a much larger weighted-average share count following the IPO; Q1 2014 also included preferred-stock accretion.
- Operating cash use increased $7.067 million. Financing provided $129.647 million in Q1 2015, principally from the January follow-on offering, which generated $129.571 million net. The company also shifted funds into marketable securities.
- At March 31, shares outstanding were 26.856 million, compared with 22.879 million at December 31, 2014.
Outlook, management commentary, risks and contingencies
- Management expected available cash, cash equivalents and marketable securities to fund operating expenses and capital needs for at least 18 months from March 31, 2015. It cautioned that this estimate depended on assumptions and funds could be used sooner. The company expected higher expenses and operating losses as development advanced and stated it would need additional financing to obtain approval and commercialize candidates.
- Beloranib was the principal clinical-stage asset: the filing described Phase 3 development for Prader-Willi syndrome (PWS), and Phase 2 development for hypothalamic injury-associated obesity and severe obesity. ZGN-839 and second-generation MetAP2 inhibitors remained early-stage. The filing reported two ongoing trials as of March 31; it also stated that the U.S. PWS Phase 3 trial reached its 102-patient enrollment target in May 2015 and that a second PWS Phase 3 trial was planned in Europe for mid-2015.
- Key risks include clinical efficacy and safety, trial delays or additional regulatory requirements, reliance on contract research organizations and manufacturers, manufacturing validation and supply, dependence on beloranib, competition, intellectual-property and licensing risks, and the need for further capital. Reported adverse events in completed beloranib Phase 2 trials included dizziness, sleep disturbances, nausea and vomiting; the company reported no serious adverse events attributed to beloranib in those completed trials.
- Beloranib license agreements could require up to $12.25 million in pre-commercialization milestones and up to $12.5 million in commercialization milestones, plus royalties and other payments if applicable. A new Boston office lease was entered into in March, effective April 15, increasing lease payments by approximately $70,000 in 2015, $100,000 in 2016 and $60,000 in 2017.
- The company reported no legal proceedings as of the filing date and no material indemnification liability accrued. It disclosed no off-balance-sheet arrangements. Foreign-exchange losses were approximately $58,000 in Q1; management estimated a 10% adverse currency movement would have increased quarterly net loss by less than $100,000.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing identifies Zafgen, Inc., not Larimar Therapeutics, Inc.
- Verify the assumed 18-month cash runway against subsequent spending, financing and clinical-development plans.
- Check subsequent results and regulatory feedback for beloranib trials, including the PWS enrollment milestone and planned European trial.
- Assess clinical safety, manufacturing readiness, licensing obligations and the company’s ability to secure additional capital before commercialization.